Krystal Biotech, Inc. (KRYS)
NasdaqGS · USD · Healthcare · Biotechnology
$316.15 (+0.79%) as of
Key statistics
- Market cap
- 9.36B
- P/E (TTM)
- 39.62
- Forward P/E
- 35.32
- EPS (TTM)
- 7.98
- Dividend yield
- 0.00%
- 52-week range
- 183.26 – 382.54
- Beta
- 0.50
- Revenue (TTM)
- 440.48M
- Profit margin
- 54.82%
- Analyst target
- $395.44
- Volume
- 18.43k
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Pittsburgh, PA, United States
- Employees
- 295
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.